Mr. Lapidus will help advance Lucid’s EsoGuard and EsoCheck commercialization efforts.
Lucid is creating a series of noninvasive diagnostic tests to identify esophageal cancer and Barrett’s esophagus.
Mr. Lapidus said: “Lucid Diagnostics’ EsoGuard and EsoCheck technologies have the potential to be game changers in the diagnosis of conditions along the spectrum from Barrett’s Esophagus to esophageal cancer, which is a growing scourge. … I look forward to working with them as they accelerate commercialization, embark on important IVD clinical trials and explore capital market strategies.”
More articles on ASCs:
The ‘new normal’ for ASCs: 16 admins on how the pandemic will change the field forever
Dr. Thomas Vikoren: Same-day TJR ‘made all the more important’ by COVID-19
Indiana orthopedic practice with surgery center to open
